Form 4: Tourmaline Bio Executive Sells All Shares in Novartis Merger

W. Bradford Middlekauff, CBO, GC, and Secretary of Tourmaline Bio, disposed of all his common stock and stock options as part of the company's acquisition by Novartis AG.

Summary

• W. Bradford Middlekauff, CBO, GC, and Secretary of Tourmaline Bio, Inc. (TRML), reported the disposition of all his beneficial ownership in the company.
• The transactions occurred on October 28, 2025, pursuant to the Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG.
• Novartis AG, through its indirect wholly-owned subsidiary Torino Merger Sub Inc., completed a cash tender offer to acquire all outstanding common stock of Tourmaline Bio for $48.00 per share.
• Middlekauff disposed of 60,988 shares and an additional 8,213 shares of common stock.
• All outstanding and unexercised employee stock options, with exercise prices of $7.90, $9.46, and $17.00, were canceled and converted into cash payments.
• The cash payment for options was calculated as the difference between the $48.00 merger consideration and the option's applicable exercise price, multiplied by the aggregate number of shares issuable upon exercise.
• Following these transactions, Middlekauff holds no beneficial ownership in Tourmaline Bio.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger where shareholders received a cash payout, indicating a positive outcome for the company's equity holders. The executive's disposition of shares is a standard procedural step in such an event.

Positives

• The merger consideration of $48.00 per share represents a significant cash payout for shareholders.
• Stock options were converted to cash, providing liquidity and value to option holders based on the difference between the merger price and exercise price.
• The acquisition by Novartis AG indicates a successful outcome for Tourmaline Bio's equity holders.

Negatives

• The company's common stock will no longer be publicly traded following the acquisition, removing future investment opportunities in Tourmaline Bio as an independent entity.
• The disposition of all shares by a key executive signifies the end of their equity stake in the acquired company.

Future Outlook

The filing indicates the completion of Tourmaline Bio's acquisition by Novartis AG, suggesting Tourmaline Bio will operate as an indirect wholly-owned subsidiary of Novartis AG, with its common stock no longer publicly traded.

Industry Context

This acquisition reflects the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines, intellectual property, or market share. Novartis AG's acquisition of Tourmaline Bio aligns with strategies to enhance therapeutic portfolios.

Comparison to Industry Standards

• The $48.00 per share merger consideration would need to be compared against Tourmaline Bio's historical stock price, analyst price targets, and valuations of comparable biotech acquisitions to assess its fairness. Without specific details on Tourmaline Bio's financials or the premium paid, a direct comparison to industry benchmarks like recent biotech M&A multiples (e.g., EV/Revenue, EV/EBITDA for similar-stage companies) is not possible from this filing alone. However, the cash tender offer structure is a standard method for such acquisitions.

Stakeholder Impact

• Shareholders: Received $48.00 cash per share, providing a definitive return on investment.
• Option Holders: Received cash payments for their vested options, based on the merger consideration exceeding the exercise price.
• Employees: While not explicitly stated, employees holding stock or options would have received similar payouts. Future employment status and benefits would be subject to Novartis AG's policies.
• Company (Tourmaline Bio): Ceases to be an independent public entity, becoming part of Novartis AG.

Next Steps

• Tourmaline Bio's common stock will be delisted from public exchanges.
• Tourmaline Bio will operate as an indirect wholly-owned subsidiary of Novartis AG.
• Integration of Tourmaline Bio's operations and assets into Novartis AG.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis AG, Merger, Acquisition, Tender Offer, SEC Form 4, Insider Trading, Stock Options, Cash Payout, Biotechnology, Pharmaceuticals